Dr James Watson
Associate Director
Co-Lead Malaria Chemoprevention Theme
RESEARCH THEME(S)
Malaria
WWARN
Chagas
BIOGRAPHY
James Watson joined IDDO in March 2023 as Associate Director.
He is a Sir Henry Dale Fellow funded by the Wellcome Trust working on improving the diagnosis and treatment of severe falciparum malaria.
James is a statistician by training and previously worked at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok for seven years before moving to the Oxford University Clinical Research Unit in Viet Nam.
His research interests also include the radical cure of Plasmodium vivax malaria, SARS-CoV-2 antivirals, Chagas disease, snakebite and adaptive trial design.
Split dosing of artemisinins does not improve antimalarial therapeutic efficacy
White, N., Watson, J., & Ashley, E. (2017). Scientific Reports, 7(12132), 1-5.
Modelling primaquine-induced haemolysis in G6PD deficiency
White, N., Watson, J., Taylor, R., Menard, D., & Kheng, S. (2017). ELife.
Approximate models and robust decisions
Watson, J., & Holmes, C. (2017). Statistical Science, 31(4), 465-489.
Pharmacometric evaluation of sulfadoxine-pyrimethamine- amodiaquine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda
Bonnington, C., Nuwa, A., Theiss-Nyland, K., Kajubi, R., Kamya, M., Nankabirwa, J., Ebong, C., Nabakooza, J., Opigo, J., Salandindi, D., Odongo, M., Sararat, C., Watson, J., Suwannasin, K., Proux, S., Koesukwiwat, U., Tarning, J., Imwong, M., Tibenderana, J., … White, N. (2025). Clinical Infectious Diseases, ciaf615.
Probabilistic classification of late treatment failure in uncomplicated falciparum malaria
Mehra, S., Taylor, A., Imwong, M., White, N., & Watson, J. (2025). Nature Communications, 16(1), 9880.
Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA)
Assmus, F., Cruz, C., Watson, J., White, N., Adehin, A., Hoglund, R., Blum de Oliveira, B., Barreira, F., Scandale, I., & Tarning, J. (2025). PLoS Neglected Tropical Diseases, 19(9), e0013522 - e0013522.
Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials
Watson, J., Cruz, C., Barreira, F., Forsyth, C., Schijman, A., Peploe, R., Assmus, F., Naylor, C., Lee, J., Mehra, S., Tarning, J., Torrico, F., Gascon, J., Ortiz, L., Ribeiro, I., Sosa-Estani, S., Tipple, C., Hugonnet, S., Guérin, P., … Asada, M. (2025). The Lancet Microbe, 101156.
Accurate measurement of viral clearance in early phase antiviral studies in COVID-19
Wongnak, P., Watson, J., Jittamala, P., Schilling, W., Seers, T., Leopold, S., & White, N. (2025). The Journal of Infectious Diseases, jiaf442.
Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens
Walker, T., Watson, J., Moore, D., Frick, M., & Jamrozik, E. (2025). Lancet Infectious Diseases, 25(7), e432 - e438.
Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers.
Watson, J., Mehdipour, P., Moss, R., Jittamala, P., Zaloumis, S., Price, D., Dini, S., Hanboonkunupakarn, B., Leungsinsiri, P., Poovorawan, K., Chotivanich, K., Bancone, G., Commons, R., Day, N., Pukrittayakamee, S., Taylor, W., White, N., & Simpson, J. (2025). Antimicrobial Agents and Chemotherapy, e0154924.
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
Jittamala, P., Boyd, S., Schilling, W., Watson, J., Ngamprasertchai, T., Siripoon, T., Luvira, V., Batty, E., Wongnak, P., Esper, L., Almeida, P., Cruz, C., Ascencao, F., Aguiar, R., Ghanchi, N., Callery, J., Singh, S., Kruabkontho, V., Ngernseng, T., … White, N. (2025). EClinicalMedicine, 80.
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2
Esmaeili, S., Owens, K., Standing, J., Lowe, D., Zhang, S., Watson, J., Schilling, W., Wagoner, J., Polyak, S., & Schiffer, J. (2025). In medRxiv.
Probabilistic classification of late treatment failure in uncomplicated malaria
Mehra, S., Taylor, A., Imwong, M., White, N., & Watson, J. (2025). In medRxiv.
A protocol for a systematic review and individual patient data meta-analysis investigating the relationship between Pfkelch13 mutations and response to artemisinin-based treatment for uncomplicated falciparum malaria
van Wyk, S., Dahal, P., Vouvoungui, J., Ayuen, D., Shokraneh, F., Aboubakar, S., Watson, J., Guerin, P., & Barnes, K. (2025). In medRxiv.
Modeling the within-host dynamics of Plasmodium vivax hypnozoite activation: an analysis of the SPf66 vaccine trial
Mehra, S., Nosten, F., Luxemburger, C., White, N., & Watson, J. (2024). Proceedings of the National Academy of Sciences, 121(51).
Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial.
Huyen, T., Trieu, H., Vuong, N., Minh Nguyet, N., Tam, D., McBride, A., Linh, N., Thuan, D., Phong, N., Trung, T., Huong, N., Vien, T., Duyen, H., Hoa, V., Watson, J., Geskus, R., Tho, P., Kestelyn, E., Qui, P., & Yacoub, S. (2024). Wellcome Open Research, 9, 689.
Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial
Huyen, T., Trieu, H., Vuong, N., Minh Nguyet, N., Tam, D., McBride, A., Linh, N., Thuan, D., Phong, N., Trung, T., Huong, N., Vien, T., Duyen, H., Hoa, V., Watson, J., Geskus, R., Tho, P., Kestelyn, E., Qui, P., & Yacoub, S. (2024). Wellcome Open Res, 9, 689.
Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis
Fadilah, I., Commons, R., Chau, N., Chu, C., Day, N., Koh, G., Green, J., Lacerda, M., Llanos-Cuentas, A., Nelwan, E., Nosten, F., Pasaribu, A., Sutanto, I., Taylor, W., Thriemer, K., Price, R., White, N., Baird, J., & Watson, J. (2024). PLoS Medicine, 21(9).
Advancing the chemotherapy of tuberculous meningitis: a consensus view
Wasserman, S., Donovan, J., Kestelyn, E., Watson, J., Aarnoutse, R., Barnacle, J., Boulware, D., Chow, F., Cresswell, F., Davis, A., Dooley, K., Figaji, A., Gibb, D., Huynh, J., Imran, D., Marais, S., Meya, D., Misra, U., Modi, M., … Wilkinson, R. (2024). Lancet Infectious Diseases, 25(1), e47 - e58.
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
Schilling, W., Mukaka, M., Callery, J., Llewelyn, M., Cruz, C., Dhorda, M., Ngernseng, T., Waithira, N., Ekkapongpisit, M., Watson, J., Chandna, A., Nelwan, E., Hamers, R., Etyang, A., Beg, M., Sow, S., Yavo, W., Allabi, A., Basnyat, B., … Tarning, J. (2024). PLoS Medicine, 21(9).
Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites
Siegel, S., Trimarsanto, H., Amato, R., Murie, K., Taylor, A., Sutanto, E., Kleinecke, M., Whitton, G., Watson, J., Imwong, M., Assefa, A., Rahim, A., Nguyen, H., Tran, T., Green, J., Koh, G., White, N., Day, N., Kwiatkowski, D., … Auburn, S. (2024). Nature Communications, 15(1).
Transmission-blocking activities of artesunate, chloroquine, and methylene blue on Plasmodium vivax gametocytes
Chaumeau, V., Wasisakun, P., Watson, J., Oo, T., Aryalamloed, S., Sue, M., Htoo, G., Tha, N., Archusuksan, L., Sawasdichai, S., Gornsawun, G., Mehra, S., White, N., & Nosten, F. (2024). Antimicrobial Agents and Chemotherapy, 68(9).
Phase 2 pilot trial to optimise pharmacometric evaluations in Chagas disease (CHARM: CHAgas disease PharMacometrics)
Cruz, C., Watson, J., Molina Romero, I., & White, N. (2024). Wellcome Open Research, 9, 342.
Rectal artesunate: lives not saved
White, N., Peto, T., & Watson, J. (2024). Transactions of the Royal Society of Tropical Medicine and Hygiene, 118(10), 639-641.
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Wongnak, P., Schilling, W., Jittamala, P., Boyd, S., Luvira, V., Siripoon, T., Ngamprasertchai, T., Batty, E., Singh, S., Kouhathong, J., Pagornrat, W., Khanthagan, P., Hanboonkunupakarn, B., Poovorawan, K., Mayxay, M., Chotivanich, K., Imwong, M., Pukrittayakamee, S., Ashley, E., … Watson, J. (2024). Lancet Infectious Diseases, 24(9), P953 - 963.
Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match
Cokljat, M., Cruz, C., Carrara, V., Puttaraska, K., Capriglioni, C., Insaurralde, S., Rousseau-Portalis, M., Roldan, A., Watson, J., Tarning, J., White, N., & Guerin, P. (2024). BMJ Global Health, 9(4), e014188.
Where will rectal artesunate suppositories save lives?
Watson, J., Peto, T., & White, N. (2024). The Lancet, 403(10432), 1137-1138.
The burden of tuberculosis in Ho Chi Minh City, Vietnam: a spatial analysis of drug-susceptible and multi-drug resistant cases between 2020 and 2023
Spies, R., Hong, H., Trieu, P., Lan, L., Lan, K., Hue, N., Huong, N., Thao, T., Quang, N., Anh, T., Vinh, T., Dang, T., Phan, T., Nguyen, P., Van, L., Thwaites, G., Nguyen, T., Watson, J., & Walker, T. (2024). Emerging Infectious Diseases, 30(3), 499-509.
The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis.
Singh, S., Boyd, S., Schilling, W., Watson, J., Mukaka, M., & White, N. (2024). The Journal of Antimicrobial Chemotherapy, 79(5), 935-945.
Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis'
Watson, J., Commons, R., Tarning, J., Simpson, J., Llanos Cuentas, A., Lacerda, M., Green, J., Koh, G., Chu, C., Nosten, F., Price, R., Day, N., & White, N. (2024). ELife, 13.
Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers
Pukrittayakamee, S., Jittamala, P., Watson, J., Hanboonkunupakarn, B., Leungsinsiri, P., Poovorawan, K., Chotivanich, K., Bancone, G., Chu, C., Imwong, M., Day, N., Taylor, W., & White, N. (2024). ELife, 12.
Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers
Pukrittayakamee, S., Jittamala, P., Watson, J., Hanboonkunupakarn, B., Leungsinsiri, P., Poovorawan, K., Chotivanich, K., Bancone, G., Chu, C., Imwong, M., Day, N., Taylor, W., & White, N. (2024). ELife, 12.
Spatial analysis of drug-susceptible and multidrug-resistant cases of tuberculosis, Ho Chi Minh City, Vietnam, 2020-2023
Spies, R., Hong, H., Trieu, P., Lan, L., Lan, K., Hue, N., Huong, N., Thao, T., Quang, N., Anh, T., Vinh, T., Ha, D., Dat, P., Hai, N., Van, L., Thwaites, G., Thuong, N., Watson, J., & Walker, T. (2024). Emerging Infectious Diseases, 30(3), 499-509.
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
Luvira, V., Schilling, W., Jittamala, P., Watson, J., Boyd, S., Siripoon, T., Ngamprasertchai, T., Almeida, P., Ekkapongpisit, M., Cruz, C., Callery, J., Singh, S., Tuntipaiboontana, R., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M., Keayarsa, S., Madmanee, W., … White, N. (2024). BMC Infectious Disease, 24(1).
Modelling the within-host dynamics ofPlasmodium vivaxhypnozoite activation: an analysis of the SPf66 vaccine trial
Mehra, S., Nosten, F., Luxemburger, C., White, N., & Watson, J. (2024). In medRxiv.
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Wongnak, P., Schilling, W., Jittamala, P., Boyd, S., Luvira, V., Siripoon, T., Ngamprasertchai, T., Batty, E., Singh, S., Kouhathong, J., Pagornrat, W., Khanthagan, P., Hanboonkunupakarn, B., Poovorawan, K., Mayxay, M., Chotivanich, K., Imwong, M., Pukrittayakamee, S., Ashley, E., … Watson, J. (2024). In medRxiv.
Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
Fadilah, I., Commons, R., Chau, N., Chu, C., Day, N., Koh, G., Green, J., Lacerda, M., Llanos-Cuentas, A., Nelwan, E., Nosten, F., Pasaribu, A., Sutanto, I., Taylor, W., Thriemer, K., Price, R., White, N., Baird, J., & Watson, J. (2024). In medRxiv.
Transmission-blocking activity of artesunate, chloroquine and methylene blue on Plasmodium vivax gametocytes
Chaumeau, V., Wasisakun, P., Watson, J., Oo, T., Aryalamloed, S., Sue, M., Htoo, G., Tha, N., Archusuksan, L., Sawasdichai, S., Gornsawun, G., Mehra, S., White, N., & Nosten, F. (2024). In bioRxiv.
Within-host modelling of primaquine-induced haemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers
Watson, J., Mehdipour, P., Moss, R., Jittamala, P., Zaloumis, S., Price, D., Dini, S., Hanboonkunupakarn, B., Leungsinsiri, P., Poovorawan, K., Chotivanich, K., Bancone, G., Commons, R., Day, N., Pukrittayakamee, S., Taylor, W., White, N., & Simpson, J. (2024). In medRxiv.
Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: an individual patient data meta-analysis of two proof of concept trials
Watson, J., Cruz, C., Barreira, F., Forsyth, C., Schijman, A., Peploe, R., Assmus, F., Naylor, C., Lee, J., Mehra, S., Tarning, J., Torrico, F., Gascon, J., Ortiz, L., Ribeiro, I., Sosa-Estani, S., Tipple, C., Hugonnet, S., Guérin, P., … White, N. (2024). In medRxiv.
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
Jittamala, P., Boyd, S., Schilling, W., Watson, J., Ngamprasertchai, T., Siripoon, T., Luvira, V., Batty, E., Wongnak, P., Esper, L., Almeida, P., Cruz, C., Ascencao, F., Aguiar, R., Ghanchi, N., Callery, J., Singh, S., Kruabkontho, V., Ngernseng, T., … White, N. (2024). In medRxiv.
Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria
Watson, J., Peto, T., & White, N. (2023). PLoS Medicine, 20(11).
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Schilling, W., Jittamala, P., Watson, J., Boyd, S., Luvira, V., Siripoon, T., Ngamprasertchai, T., Batty, E., Cruz, C., Callery, J., Singh, S., Saroj, M., Kruabkontho, V., Ngernseng, T., Tanglakmankhong, N., Tubprasert, J., Abdad, M., Madmanee, W., Kouhathong, J., … White, N. (2023). Lancet Infectious Diseases, 24(1), 36-45.
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis
Commons, R., Rajasekhar, M., Edler, P., Abreha, T., Awab, G., Baird, J., Barber, B., Chu, C., Cui, L., Daher, A., Gonzalez-Ceron, L., Grigg, M., Hwang, J., Karunajeewa, H., Lacerda, M., Ladeia-Andrade, S., Lidia, K., Llanos-Cuentas, A., Longley, R., … Price, R. (2023). Lancet Infectious Diseases, 24(2), 172-183.
Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
Rajasekhar, M., Simpson, J., Ley, B., Edler, P., Chu, C., Abreha, T., Awab, G., Baird, J., Bancone, G., Barber, B., Grigg, M., Hwang, J., Karunajeewa, H., Lacerda, M., Ladeia-Andrade, S., Llanos-Cuentas, A., Pukrittayakamee, S., Rijal, K., Saravu, K., … Price, R. (2023). Lancet Infectious Diseases, 24(2), 184-195.
Evidence based optimal dosing of intravenous artesunate in children with severe falciparum malaria
Haghiri, A., Price, D., Fitzpatrick, P., Dini, S., Rajasekhar, M., Fanello, C., Tarning, J., Watson, J., White, N., & Simpson, J. (2023). Clinical Pharmacology and Therapeutics.
Définition d’un jeu universel de critères de décision de base pour les essais cliniques sur les morsures de serpent: traduction par Jean-Philippe Chippaux de l’article de Abouyannis M, et al. A global core outcome measurement set for snakebite clinical trials
Abouyannis, M., Esmail, H., Hamaluba, M., Ngama, M., Mwangudzah, H., Mumba, N., Yeri, B., Mwalukore, S., Alphan, H., Aggarwal, D., Alcoba, G., Cammack, N., Chippaux, J.-P., Coldiron, M., Gutiérrez, J., Habib, A., Harrison, R., Isbister, G., Lavonas, E., … Lalloo, D. (2023). Médecine Tropicale et Santé Internationale, 3(3).
Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)
Jittamala, P., Schilling, W., Watson, J., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P., Ekkapongpisit, M., Cruz, C., Callery, J., Boyd, S., Anunsittichai, O., Hongsuwan, M., Singhaboot, Y., Pagornrat, W., Tuntipaiboontana, R., Kruabkontho, V., Ngernseng, T., Tubprasert, J., … White, N. (2023). The Journal of Infectious Diseases, 228(10), 1318-1325.
The CARAMAL study could not assess the effectiveness of rectal artesunate in treating suspected severe malaria
Watson, J., Peto, T., & White, N. (2023). BMC Medicine, 21(1).
Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis.
Thwaites, G., Watson, J., Thuong Thuong, N., Huynh, J., Walker, T., & Phu, N. (2023). Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 29(7), 826-828.
Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis
Thwaites, G., Watson, J., Thuong, N., Huynh, J., Walker, T., & Phu, N. (2023). Clinical Microbiology and Infection, 29(7), 826-828.
Lineage-informative microhaplotypes for spatio-temporal surveillance of Plasmodium vivax malaria parasites.
Siegel, S., Amato, R., Trimarsanto, H., Sutanto, E., Kleinecke, M., Murie, K., Whitton, G., Taylor, A., Watson, J., Imwong, M., Assefa, A., Rahim, A., Chau, N., Hien, T., Green, J., Koh, G., White, N., Day, N., Kwiatkowski, D., … Auburn, S. (2023). MedRxiv, 4(03-29), 2023.03.13.23287179.
Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)
Schilling, W., Jittamala, P., Watson, J., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., … White, N. (2023). ELife, 12.
WHO should accelerate, not stall, rectal artesunate deployment for pre-referral treatment of severe malaria
Peto, T., Watson, J., White, N., & Dondorp, A. (2023). Transactions of The Royal Society of Tropical Medicine and Hygiene, 117(7), 536-538.
A global core outcome measurement set for snakebite clinical trials
Abouyannis, M., Esmail, H., Hamaluba, M., Ngama, M., Mwangudzah, H., Mumba, N., Yeri, B., Mwalukore, S., Alphan, H., Aggarwal, D., Alcoba, G., Cammack, N., Chippaux, J.-P., Coldiron, M., Gutierrez, J., Habib, A., Harrison, R., Ibister, G., Lavonas, E., … Lalloo, D. (2023). Lancet Global Health, 11(2), E296 - E300.
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial
Luvira, V., Schilling, W., Jittamala, P., Watson, J., Boyd, S., Siripoon, T., Ngamprasertchai, T., Almeida, P., Ekkapongpisit, M., Cruz, C., Callery, J., Singh, S., Tuntipaiboontana, R., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M., Keayarsa, S., Madmanee, W., … White, N. (2023). In Research Square.
Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency
Pukrittayakamee, S., Jittamala, P., Watson, J., Hanboonkunupakarn, B., Leungsinsiri, P., Poovorawan, K., Chotivanich, K., Bancone, G., Chu, C., Imwong, M., Day, N., Taylor, W., & White, N. (2023). In medRxiv.
Population heterogeneity in Plasmodium vivax relapse risk
Stadler, E., Cromer, D., Mehra, S., Adekunle, A., Flegg, J., Anstey, N., Watson, J., Chu, C., Mueller, I., Robinson, L., Schlub, T., Davenport, M., & Khoury, D. (2022). PLoS Neglected Tropical Diseases, 16(12).
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis
Watson, J., Commons, R., Tarning, J., Simpson, J., Llanos Cuentas, A., Lacerda, M., Green, J., Koh, G., Chu, C., Nosten, F., Price, R., Day, N., & White, N. (2022). ELife, 11.
The prognostic and diagnostic value of intraleukocytic malaria pigment in patients with severe falciparum malaria
Srinamon, K., Watson, J., Silamut, K., Intharabut, B., Phu, N., Diep, P., Lyke, K., Fanello, C., von Seidlein, L., Chotivanich, K., Dondorp, A., Day, N., & White, N. (2022). Nature Communications, 13.
Substantial misdiagnosis of severe malaria in African children
White, N., Watson, J., Uyoga, S., Williams, T., & Maitland, K. (2022). The Lancet, 400(10355), 807.
BIRC6 modifies risk of invasive bacterial infection in Kenyan children
Gilchrist, J., Kariuki, S., Watson, J., Band, G., Uyoga, S., Ndila, C., Mturi, N., Mwarumba, S., Mohammed, S., Mosobo, M., Alasoo, K., Rockett, K., Mentzer, A., Kwiatkowski, D., Hill, A., Maitland, K., Scott, J., & Williams, T. (2022). ELife, 11(11).
Higher-dose primaquine to prevent relapse of Plasmodium vivax malaria
Watson, J., & White, N. (2022). New England Journal of Medicine, 387(3), 282-283.
Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
Guérin, P., McLean, A., Rashan, S., Lawal, A., Watson, J., Strub-Wourgaft, N., & White, N. (2022). PLOS Global Public Health, 2(7).
Stopping prereferral rectal artesunate - a grave error
Watson, J., Warsame, M., Peto, T., Onyamboko, M., Fanello, C., Dondorp, A., & White, N. (2022). BMJ Global Health, 7(7).
Characterizing SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies
Watson, J., Kissler, S., Day, N., Grad, Y., & White, N. (2022). Antimicrobial Agents and Chemotherapy, 66(7).
The impact of malaria-protective red blood cell polymorphisms on parasite biomass in children with severe Plasmodium falciparum malaria
Uyoga, S., Watson, J., Wanjiku, P., Rop, J., Makale, J., Macharia, A., Kariuki, S., Nyutu, G., Shebe, M., Mosobo, M., Mturi, N., Rockett, K., Woodrow, C., Dondorp, A., Maitland, K., White, N., & Williams, T. (2022). Nature Communications, 13(1).
Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers
Chotsiri, P., Tarning, J., Hoglund, R., Watson, J., & White, N. (2022). Clinical Pharmacology & Therapeutics, 112(4), 824-835.
Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials
White, N., Watson, J., & Baird, J. (2022). British Journal of Clinical Pharmacology, 88(6), 2657-2664.
Risk of Plasmodium vivax recurrences follows a 30-70 rule and indicates relapse heterogeneity in the population
Stadler, E., Cromer, D., Mehra, S., Adekunle, A., Flegg, J., Anstey, N., Watson, J., Chu, C., Mueller, I., Robinson, L., Schlub, T., Davenport, M., & Khoury, D. (2022). In medRxiv.
Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
Schilling, W., Jittamala, P., Watson, J., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., … White, N. (2022). In medRxiv.
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis
Watson, J., Commons, R., Tarning, J., Simpson, J., Cuentas, A., Lacerda, M., Green, J., Koh, G., Chu, C., Nosten, F., Price, R., Day, N., & White, N. (2022). In medRxiv.
BIRC6 modifies risk of invasive bacterial infection in Kenyan children
Gilchrist, J., Kariuki, S., Watson, J., Band, G., Uyoga, S., Ndila, C., Mturi, N., Mwarumba, S., Mohammed, S., Mosobo, M., Rockett, K., Mentzer, A., Kwiatkowski, D., Hill, A., Maitland, K., Scott, J., & Williams, T. (2022). In medRxiv.
The impact of malaria-protective red blood cell polymorphisms on parasite biomass in children with severe Plasmodium falciparum malaria
Uyoga, S., Watson, J., Wanjiku, P., Rop, J., Makale, J., Macharia, A., Kariuki, S., Nyutu, G., Shebe, M., Mosobo, M., Mturi, N., Rockett, K., Woodrow, C., Dondorp, A., Maitland, K., White, N., & Williams, T. (2022). In medRxiv.
Asexual stage synchronicity in symptomatic and asymptomatic falciparum malaria
Watson, J., & White, N. (2022). In medRxiv.
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
Jittamala, P., Schilling, W., Watson, J., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P., Ekkapongpisit, M., Cruz, C., Callery, J., Boyd, S., Anunsittichai, O., Hongsuwan, M., Singhaboot, Y., Pagornrat, W., Tuntipaiboontana, R., Kruabkontho, V., Ngernseng, T., Tubprasert, J., … White, N. (2022). In medRxiv.
Severe malaria, pascalian therapeutics, and the US Food and Drug Administration (FDA)
White, N., Watson, J., & Simpson, J. (2022). Clinical Infectious Diseases, 75(2), 358-358.
Falciparum malaria mortality in sub-Saharan Africa in the pretreatment era
Watson, J., White, N., & Dondorp, A. (2021). Trends in Parasitology, 38(1), 11-14.
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Schilling, W., Callery, J., Chandna, A., Hamers, R., Watson, J., & White, N. (2021). Wellcome Open Research, 6, 71-71.
Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria
Chu, C., Watson, J., Phyo, A., Win, H., Yotyingaphiram, W., Thinraow, S., Soe, N., Aung, A., Wilaisrisak, P., Kraft, K., Imwong, M., Hanpithakpong, W., Blessborn, D., Tarning, J., Proux, S., Ling, C., Nosten, F., & White, N. (2021). Antimicrobial Agents and Chemotherapy, 65(11).
Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision
Watson, J., Ndila, C., Uyoga, S., Macharia, A., Nyutu, G., Shebe, M., Ngetsa, C., Mturi, N., Peshu, N., Tsofa, B., Rockett, K., Leopold, S., Kingston, H., George, E., Maitland, K., Day, N., Dondorp, A., Bejon, P., Williams, T., … White, N. (2021). ELife, 10.
Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision.
Watson, J., Ndila, C., Uyoga, S., Macharia, A., Nyutu, G., Mohammed, S., Ngetsa, C., Mturi, N., Peshu, N., Tsofa, B., Rockett, K., Leopold, S., Kingston, H., George, E., Maitland, K., Day, N., Dondorp, A., Bejon, P., Williams, T., … White, N. (2021). ELife, 10.
Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria
Chu, C., Watson, J., Phyo, A., Win, H., Yotyingaphiram, W., Thinraow, S., Soe, N., Aung, A., Wilaisrisak, P., Puaprasert, K., Imwong, M., Hanpithakpong, W., Blessborn, D., Tarning, J., Proux, S., Ling, C., Nosten, F., & White, N. (2021). In medRxiv.
Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
Guérin, P., McLean, A., Rashan, S., Lawal, A., Watson, J., Strub-Wourgaft, N., & White, N. (2021).
Tafenoquine for the prevention of Plasmodium vivax malaria relapse
Watson, J., Nekkab, N., & White, M. (2021). Lancet Microbe, 2(5), E175 - E176.
Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria
Awab, G., Aaram, F., Jamornthanyawat, N., Suwannasin, K., Pagornrat, W., Watson, J., Woodrow, C., Dondorp, A., Day, N., Imwong, M., & White, N. (2021). ELife, 10.
Prediction of disease severity in young children presenting with acute febrile illness in resource-limited settings: a protocol for a prospective observational study
Chandna, A., Aderie, E., Ahmad, R., Arguni, E., Ashley, E., Cope, T., Dat, V., Day, N., Dondorp, A., Illanes, V., De Jesus, J., Jimenez, C., Kain, K., Suy, K., Koshiaris, C., Lasry, E., Mayxay, M., Mondal, D., Perera, R., … Lubell, Y. (2021). BMJ Open, 11(1).
Optimal design for phase 2 studies of SARS-CoV-2 antiviral drugs
Watson, J., Kissler, S., Day, N., Grad, Y., & White, N. (2021).
Improving the diagnosis of severe malaria in African children using platelet counts and plasma Pf HRP2 concentrations
Watson, J., Uyoga, S., Wanjiku, P., Makale, J., Nyutu, G., Mturi, N., George, E., Woodrow, C., Day, N., Bejon, P., Opoka, R., Dondorp, A., John, C., Maitland, K., Williams, T., & White, N. (2021). In medRxiv.
Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials
White, N., Watson, J., & Baird, K. (2021). In Authorea.
The prognostic and diagnostic value of intraleukocytic malaria pigment: an individual patient data pooled meta-analysis of 32,000 patients with severe falciparum malaria in Africa and Asia
Srinamon, K., Watson, J., Silamut, K., Intharabut, B., Phu, N., Diep, P., Lyke, K., Fanello, C., von Seidlein, L., Chotivanich, K., Dondorp, A., Day, N., & White, N. (2021). In medRxiv.
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions.
Schilling, W., Callery, J., Chandna, A., Hamers, R., Watson, J., & White, N. (2021). Wellcome Open Research, 6, 71.
Time-to-death is a potential confounder in observational studies of blood transfusion in severe malaria
Watson, J., Leopold, S., Dondorp, A., & White, N. (2021). The Lancet Haematology, 8(1), e12.
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions.
Schilling, W., Callery, J., Chandna, A., Hamers, R., Watson, J., & White, N. (2021). Wellcome Open Research, 6, 71.
Questioning the claimed superiority of malaria parasite ex vivo viability reduction over observed parasite clearance rate?
White, N., & Watson, J. (2020). The Journal of Infectious Diseases, 224(4), 738-739.
Is malaria parasite ex-vivo viability reduction really "superior" to observed parasite clearance rate?
White, N., & Watson, J. (2020). The Journal of Infectious Diseases.
Machine learning analysis plans for randomised controlled trials: detecting treatment effect heterogeneity with strict control of type I error
Watson, J., & Holmes, C. (2020). Trials, 21(1), 156.
Graphing and reporting heterogeneous treatment effects through reference classes
Watson, J., & Holmes, C. (2020). Trials, 21(1), 386.
A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar
Watson, J., Lamb, T., Holmes, J., Warrell, D., Thwin, K., Aung, Z., Oo, M., Nwe, M., Smithuis, F., & Ashley, E. (2020). PLoS Neglected Tropical Diseases, 14(11).
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)
Schilling, W., Callery, J., Taylor, W., Mukaka, M., Ekkapongpisit, M., Watson, J., Chandna, A., Panapipat, S., Tubprasert, J., Yuentrakul, P., Waithira, N., Cope, T., Dhorda, M., Cruz, C., von Seidlein, L., Milton, J., LLewelyn, M., Adler, A., Chotivanich, K., … White, N. (2020). Wellcome Open Research, 5, 241-241.
A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices
Watson, J., Taylor, A., Ashley, E., Dondorp, A., Buckee, C., White, N., & Holmes, C. (2020). PLoS Genetics, 16(10).
Effect of hydroxychloroquine in hospitalized patients with COVID-19
Horby, P., Mafham, M., Linsell, L., Bell, J., Staplin, N., Emberson, J., Tarning, J., Watson, J., White, N., Juszczak, E., Haynes, R., & Landray, M. (2020). New England Journal of Medicine, 383(21), 2030-2040.
Correction to: Graphing and reporting heterogeneous treatment effects through reference classes.
Watson, J., & Holmes, C. (2020). Trials, 21(1), 865.
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
White, N., Watson, J., Hoglund, R., Chan, X., Cheah, P., & Tarning, J. (2020). PLOS Medicine, 17(9).
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Horby, P., Mafham, M., Linsell, L., Bell, J., Staplin, N., Emberson, J., Wiselka, M., Ustianowski, A., Elmahi, E., Prudon, B., Whitehouse, A., Felton, T., Williams, J., Faccenda, J., Underwood, J., Baillie, J., Chappell, L., Faust, S., Jaki, T., … Landray, M. (2020). Cold Spring Harbor Laboratory.
Concentration-dependent mortality of chloroquine in overdose
Watson, J., Tarning, J., Hoglund, M., Baud, F., Megarbane, B., Clemessy, J.-L., & White, N. (2020). ELife, 9.
Non-adherence in non-inferiority trials: pitfalls and recommendations
Mo, Y., Lim, C., Watson, J., White, N., & Cooper, B. (2020). BMJ, 370.
Estimating the proportion of plasmodium vivax recurrences caused by relapse: A systematic review and meta-analysis
Commons, R., Simpson, J., Watson, J., White, N., & Price, R. (2020). American Journal of Tropical Medicine and Hygiene.
A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices
Watson, J., Taylor, A., Ashley, E., Dondorp, A., Buckee, C., White, N., & Holmes, C. (2020).
Concomitant bacteremia in adults with severe falciparum malaria
Phu, N., Day, N., Tuan, P., Mai, N., Chau, T., Van Chuong, L., Vinh, H., Loc, P., Sinh, D., Hoa, N., Waller, D., Wain, J., Jeyapant, A., Watson, J., Farrar, J., Hien, T., Parry, C., & White, N. (2020). Clinical Infectious Diseases, 71(9), e465 - e470.
A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria
Diez Benavente, E., Campos, M., Phelan, J., Nolder, D., Dombrowski, J., Marinho, C., Sriprawat, K., Taylor, A., Watson, J., Roper, C., Nosten, F., Sutherland, C., Campino, S., & Clark, T. (2020). PLoS Genetics, 16(2).
A semi-supervised learning framework for quantitative structure-activity regression modelling
Watson, O., Cortes-Ciriano, I., & Watson, J. (2020). In arXiv.
A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: application to a dose-finding trial for a novel Russell’s viper antivenom in Myanmar
Watson, J., Lamb, T., Holmes, J., Warrell, D., Thwin, K., Aung, Z., Nwe, M., Smithuis, F., & Ashley, E. (2020).
Concentration-dependent mortality of chloroquine in overdose
Watson, J., Tarning, J., Hoglund, R., Baud, F., Mégarbane, B., Clemessy, J.-L., & White, N. (2020).
The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos
Von Seidlein, L., Peerawaranun, P., Mukaka, M., Nosten, F., Nguyen, T.-N., Hien, T., Tripura, R., Peto, T., Pongvongsa, T., Phommasone, K., Mayxay, M., Imwong, M., Watson, J., Pukrittayakamee, S., Day, N., & Dondorp, A. (2019). Malaria Journal, 18.
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically
Taylor, A., Watson, J., Chu, C., Puaprasert, K., Duanguppama, J., Day, N., Nosten, F., Neafsey, D., Buckee, C., Imwong, M., & White, N. (2019). Nature Communications, 10(1).
Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies.
Leopold, S., Watson, J., Jeeyapant, A., Simpson, J., Phu, N., Hien, T., Day, N., Dondorp, A., & White, N. (2019). PLoS Medicine, 16(8).
The haematological consequences of plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
Commons, R., Simpson, J., Thriemer, K., Chu, C., Douglas, N., Abreha, T., Alemu, S., Añez, A., Anstey, N., Aseffa, A., Assefa, A., Awab, G., Baird, K., Barber, B., Borghini-Fuhrer, I., D’Alessandro, U., Dahal, P., Daher, A., De Vries, P., … Guerin, P. (2019). BMC Medicine, 17.
Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria
Watson, J., & Taylor, A. (2019). New England Journal of Medicine, 380(19), 1875-1876.
A decision-theoretic approach to the evaluation of machine learning algorithms in computational drug discovery
Watson, O., Cortes-Ciriano, I., Taylor, A., & Watson, J. (2019). Bioinformatics, 35(22), 4656-4663.
Pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole
Watson, J., Strub-Wourgraft, N., Tarral, A., Ribeiro, I., Tarning, J., & White, N. (2019). Antimicrobial Agents and Chemotherapy, 63(4), e02515 - 18.
Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria
Watson, J., Leopold, S., Simpson, J., Day, N., Dondorp, A., & White, N. (2019). ELife, 8.
Assessing non-adherence in non-inferiority trials: implications from a simulation study
Mo, Y., Lim, C., Watson, J., & Cooper, B. (2019). TRIALS, 20.
Estimating the probable cause of recurrence in Plasmodium vivax malaria: relapse, reinfection or recrudescence?
Taylor, A., Watson, J., Chu, C., Puaprasert, K., Duanguppama, J., Day, N., Nosten, F., Neafsey, D., Buckee, C., Imwong, M., & White, N. (2018).
A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole
Watson, J., Strub-Wourgraft, N., Tarral, A., Ribeiro, I., Tarning, J., & White, N. (2018).
Chloroquine versus hihydroartemisinin-piperaquine with standard high-dose Primaquine given either for 7 days or 14 days in Plasmodium vivax malaria
Chu, C., Phyo, A., Turner, C., Win, H., Poe, N., Yotyingaphiram, W., Thinraow, S., Wilairisak, P., Raksapraidee, R., Carrara, V., Paw, M., Wiladphaingern, J., Proux, S., Bancone, G., Sriprawat, K., Lee, S., Jeeyapant, A., Watson, J., Tarning, J., … White, N. (2018). Clinical Infectious Diseases, 68(8), 1311-1319.
A decision theoretic approach to model evaluation in computational drug discovery
Watson, O., Cortes-Ciriano, I., Taylor, A., & Watson, J. (2018). In arXiv.
Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in plasmodium vivax malaria
Chu, C., Phyo, A., Lwin, K., Win, H., San, T., Aung, A., Raksapraidee, R., Carrara, V., Bancone, G., Watson, J., Moore, K., Wiladphaingern, J., Proux, S., Sriprawat, K., Winterberg, M., Cheah, P., Chue, A., Tarning, J., Imwong, M., … White, N. (2018). Clinical Infectious Diseases, 67(10), 1543-1549.
Machine learning for randomised controlled trials: identifying treatment effectheterogeneity with strict control of type I error
Holmes, C., & Watson, J. (2018). 330795.
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
Watson, J., Taylor, W., Bancone, G., Chu, C., Jittamala, P., & White, N. (2018). PLoS Neglected Tropical Diseases, 12(4), e0006440.
Characterising blood stage antimalarial drug minimum inhibitory concentrations in vivo using reinfection patterns
Watson, J., Chu, C., Tarning, J., & White, N. (2018). Antimicrobial Agents and Chemotherapy, 62(7), e02476 - 17.
Split dosing of artemisinins does not improve antimalarial therapeutic efficacy
White, N., Watson, J., & Ashley, E. (2017). Scientific Reports, 7(12132), 1-5.
Antimalarial resistance unlikely to explain U.K. artemether-lumefantrine failures
van der Pluijm, R., Watson, J., & Woodrow, C. (2017). Antimicrobial Agents and Chemotherapy, 61(7), e00721 - 17.
Modelling primaquine-induced haemolysis in G6PD deficiency
White, N., Watson, J., Taylor, R., Menard, D., & Kheng, S. (2017). ELife.
Rejoinder: Approximate Models and Robust Decisions
Watson, J., & Holmes, C. (2017). Statistical Science, 31(4), 516-520.
Approximate models and robust decisions
Watson, J., & Holmes, C. (2017). Statistical Science, 31(4), 465-489.
Characterizing variation of nonparametric random probability measures using the Kullback–Leibler divergence
Watson, J., Nieto-Barajas, L., & Holmes, C. (2016). Statistics, 51(3), 558-571.
A decision theoretic approach to model evaluation in computational drug
discovery
Watson, O., Cortes-Ciriano, I., Taylor, A., & Watson, J. (n.d.).
Characterising viral clearance kinetics in acute influenza
Wongnak, P., Seers, T., Jittamala, P., Imwong, M., Schilling, W., Watson, J., & White, N. (n.d.). In medRxiv.
A semi-supervised learning framework for quantitative structure-activity
regression modelling
Watson, O., Cortes-Ciriano, I., & Watson, J. (n.d.).
Strong gene dose dependent protective effect of Mediterranean type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria
Awab, G., Aaram, F., Jamornthanyawat, N., Suwannasin, K., Pagornrat, W., Watson, J., Woodrow, C., Dondorp, A., Day, N., Imwong, M., & White, N. (n.d.).
Graphing and reporting heterogeneous treatment effects through reference classes
Watson, J., & Holmes, C. (n.d.). In bioRxiv.